Eledon Pharmaceuticals Reports Widened 2025 Net Loss Amid Mixed Phase 2 Trial Results and Ongoing Funding Needs
ELDN has more than doubled off its 52-week low of $1.35.
Summary
Eledon Pharmaceuticals reported a widened net loss of $45.6 million for 2025, highlighted mixed Phase 2 clinical trial results for its lead candidate, and indicated a need for further financing despite a recent $53.6 million offering.
Key Events · Earnings and Guidance · ELDN
-
Widened Net Loss in 2025
The company reported a net loss of $45.6 million for the year ended December 31, 2025, a significant increase from $36.2 million in 2024, primarily due to higher research and development expenses.
-
Mixed Phase 2 Clinical Trial Results for Tegoprubart
The Phase 2 BESTOW trial for kidney transplant rejection did not meet its primary efficacy endpoint (eGFR statistical significance). However, it demonstrated a favorable safety profile and positive secondary outcomes, including reduced new-onset diabetes and tremor compared to standard-of-care tacrolimus.
-
Significant Capital Raise and Future Funding Needs
Eledon completed a $53.6 million net proceeds underwritten offering in November 2025. Despite this, management explicitly stated that additional financing will be required to fund future operations, particularly for the ALS clinical development program.
-
High Potential Dilution from Outstanding Warrants
As of December 31, 2025, there are over 51.7 million common stock and pre-funded warrants outstanding. If all were exercised, this would represent a potential dilution of approximately 68.6% to current common stockholders.
Analysis · ELDN · Life Sciences
Eledon Pharmaceuticals' annual report reveals a significant widening of its net loss in 2025, driven by increased R&D expenses. While the company secured substantial financing through a November 2025 offering, it explicitly states the need for additional capital to fund future operations, especially for its ALS program. The Phase 2 BESTOW trial for kidney transplant rejection, a key program, missed its primary efficacy endpoint, although secondary outcomes and safety data were positive. This mixed clinical signal, coupled with high potential dilution from outstanding warrants, presents a challenging outlook despite a current 12-month cash runway. Investors should monitor future financing efforts and the path forward for tegoprubart's clinical development.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ELDN was trading at $2.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $214M. The 52-week trading range was $1.35 to $4.60. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.